Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Revenue (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Revenue for 13 consecutive years, with $2000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Revenue rose 100.0% year-over-year to $2000.0, compared with a TTM value of $6000.0 through Sep 2025, changed 0.0%, and an annual FY2024 reading of $10000.0, up 100.0% over the prior year.
  • Revenue was $2000.0 for Q1 2025 at Alaunos Therapeutics, down from $4000.0 in the prior quarter.
  • Across five years, Revenue topped out at $2.9 million in Q3 2022 and bottomed at -$11000.0 in Q4 2022.
  • Average Revenue over 5 years is $331600.0, with a median of $3000.0 recorded in 2021.
  • Peak annual rise in Revenue hit 631.41% in 2022, while the deepest fall reached 650.0% in 2022.
  • Year by year, Revenue stood at $2000.0 in 2021, then crashed by 650.0% to -$11000.0 in 2022, then soared by 109.09% to $1000.0 in 2023, then soared by 300.0% to $4000.0 in 2024, then crashed by 50.0% to $2000.0 in 2025.
  • Business Quant data shows Revenue for TCRT at $2000.0 in Q1 2025, $4000.0 in Q4 2024, and $4000.0 in Q2 2024.